News
FDA approves brensocatib for non-cystic fibrosis bronchiectasis
The FDA granted approval to brensocatib for treating adults and children aged at least 12 years with non-cystic fibrosis bronchiectasis, marking the first treatment approved for this indication, according to a press release from Insmed.
Stocktwits on MSN2d
HC Wainwright Doubles Price Target On Insmed After Brinsupri Approval: Retail Expects Stock To Hit $150 By End Of Week
H.C. Wainwright on Wednesday doubled its price target on Insmed (INSM) to $240 from $120 while keeping a ‘Buy’ rating on the ...
Conroy Wong, MB, ChB, from Middlemore Hospital in Auckland, New Zealand, and colleagues conducted a randomized trial involving patients with non-cystic fibrosis bronchiectasis. Participants, who ...
Non-Cystic Fibrosis Bronchiectasis companies in the treatment market are NovaBiotics Ltd, Synspira Therapeutics, Parion Sciences, Chiesi Farmaceutic, CSL Behring, Haisco Pharmaceutical, SolAeroMed ...
Fosun Pharma Industrial has entered a licence agreement to grant ex-China rights for its respiratory drug, XH-S004, to Expedition.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback